T. Fox

The risk of depression, suicidal ideation and suicide attempt in patients with psoriasis, psoriatic arthritis or ankylosing spondylitis

Jashin J. Wu, Robert B. Penfold, Paola Primatesta et al. · Journal of the European Academy of Dermatology and Venereology · 2017 · 129 citations

Medicine, Health Sciences, Psychiatry +15

Secukinumab sustains good efficacy and favourable safety in moderate-to-severe psoriasis after up to 3 years of treatment: results from a double-blind extension study

Robert Bissonnette, Thomas A. Luger, Diamant Thaçi et al. · British Journal of Dermatology · 2017 · 69 citations

Pharmacy, Pharmacology, Pharmacotherapy +10

Patient perceptions of clear/almost clear skin in moderate‐to‐severe plaque psoriasis: results of the Clear About Psoriasis worldwide survey

April W. Armstrong, Suzanne Jarvis, Wolf‐­Henning Boehncke et al. · Journal of the European Academy of Dermatology and Venereology · 2018 · 64 citations · Full text

Medicine, Dermatology, Clinical Epidemiology +6

Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits minimal immunogenicity in patients with moderate-to-severe plaque psoriasis

Kristian Reich, Andrew Blauvelt, April W. Armstrong et al. · British Journal of Dermatology · 2016 · 59 citations

Life Sciences, Immunology, Pharmacology +17

Secukinumab administration by autoinjector maintains reduction of plaque psoriasis severity over 52 weeks: results of the randomized controlled <scp>JUNCTURE</scp> trial

J.‐P. Lacour, C. Paul, S. Jazayeri et al. · Journal of the European Academy of Dermatology and Venereology · 2017 · 57 citations

Medicine, Dermatology, Pharmacotherapy +16